EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word (s): Quarterly / Interim Statement/Quarter Results SCHOTT Pharma records good start into fiscal year and confirms full year outlook 13.02.2025 / ...

FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2% ...